- Home
- NTIP vs NRXP Comparison
NTIP vs NRXP Comparison
Compare NTIP & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- NRXP
- Stock Information
- Founded
- NTIP 1990
- NRXP 2015
- Country
- NTIP United States
- NRXP United States
- Employees
- NTIP N/A
- NRXP N/A
- Industry
- NTIP Multi-Sector Companies
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- NRXP Health Care
- Exchange
- NTIP Nasdaq
- NRXP Nasdaq
- Market Cap
- NTIP 32.0M
- NRXP 58.5M
- IPO Year
- NTIP 1998
- NRXP N/A
- Fundamental
- Price
- NTIP $1.43
- NRXP $2.85
- Analyst Decision
- NTIP
- NRXP Strong Buy
- Analyst Count
- NTIP 0
- NRXP 4
- Target Price
- NTIP N/A
- NRXP $28.50
- AVG Volume (30 Days)
- NTIP 36.9K
- NRXP 137.7K
- Earning Date
- NTIP 08-11-2025
- NRXP 08-13-2025
- Dividend Yield
- NTIP 7.04%
- NRXP N/A
- EPS Growth
- NTIP N/A
- NRXP N/A
- EPS
- NTIP N/A
- NRXP N/A
- Revenue
- NTIP $250,000.00
- NRXP N/A
- Revenue This Year
- NTIP N/A
- NRXP N/A
- Revenue Next Year
- NTIP N/A
- NRXP $230.95
- P/E Ratio
- NTIP N/A
- NRXP N/A
- Revenue Growth
- NTIP N/A
- NRXP N/A
- 52 Week Low
- NTIP $1.16
- NRXP $1.10
- 52 Week High
- NTIP $1.78
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- NTIP 62.66
- NRXP 38.54
- Support Level
- NTIP $1.40
- NRXP $2.89
- Resistance Level
- NTIP $1.46
- NRXP $3.15
- Average True Range (ATR)
- NTIP 0.06
- NRXP 0.14
- MACD
- NTIP 0.01
- NRXP -0.04
- Stochastic Oscillator
- NTIP 80.43
- NRXP 10.22
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.